Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.00-$9.50 to $9.50-$9.75 vs $9.30 Est; Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $225.000M-$250.000M vs $288.592M Est
Benzinga Newsdesk 2 days ago
NewsGuidance
Ligand Pharmaceuticals (NASDAQ:LGND) raises FY2026 Adj EPS guidance from $9.00-$9.50 to $9.50-$9.75 vs $9.30 analyst estimate. Lowers FY2026 sales outlook from $270.000 million-$310.000 million to $225.000
Ligand Pharmaceuticals (NASDAQ:LGND) raises FY2026 Adj EPS guidance from $9.00-$9.50 to $9.50-$9.75 vs $9.30 analyst estimate. Lowers FY2026 sales outlook from $270.000 million-$310.000 million to $225.000 million-$250.000 million vs $288.592 million estimate.